Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 31% on Thursday . The company traded as high as C$0.23 and last traded at C$0.19. 480,687 shares traded hands during mid-day trading, a decline of 9% from the average session volume of 525,664 shares. The stock had previously closed at C$0.15.
Hemostemix Trading Down 7.9 %
The stock has a 50-day simple moving average of C$0.20 and a two-hundred day simple moving average of C$0.12. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The firm has a market cap of C$25.50 million, a PE ratio of -5.10 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Insider Trades May Not Tell You What You Think
- DuPont’s Electronics Spinoff: The Start of Something Big
- What Are Earnings Reports?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
